HEOR & RWE: Global Sourcing Strategies and Best Practices

As incorporating Real World Evidence (RWE) in Health Economics and Outcomes Research (HEOR) strategy is gaining attention within the life sciences, and pharma in particular, global research organizations need to learn how to navigate the complexities of gathering and analyzing this data to demonstrate product value. It is becoming apparent to many organizations that one of the best solutions is to leverage experienced service providers, who are often also knowledgeable about the Health Technology Assessment (HTA) and regulatory requirements across various regions. These challenges make outsourcing expert service providers inevitable and a key to driving the value story of products. However, outsourcing can lead to long contracting times and difficulties in locating the right supplier, especially as the demand for RWE as part of an HEOR strategy increases. All of this leads one to ask: how does outsourcing support RWE for generating value evidence when the practice of outsourcing itself presents its own challenges?

Some questions that will be answered include:

• What is RWE and HEOR?
• What are some of the major challenges when sourcing HEOR and RWE?
• What sourcing trends are occurring in the global strategy and regulation of RWE (including HEOR, epidemiology, market access and other RWE)?
• What are the best practices and strategies when sourcing HEOR and RWE services?

Speakers

Julie Carter, Category Director, RWE & HEOR, Scientist.com

Julie possesses an MPH with a focus on Epidemiology and has extensive experience in research, management consulting and IT services. Prior to joining Scientist.com, she was an internal consultant driving Real World Evidence (RWE) projects at Bayer, focusing on strategy, data implementation, new technology rollout, training and change management. In addition to her experience within RWE, she has assisted and at times led observational and clinical research while at the Centers for Disease Control and Prevention, Weill Cornell Medicine and a leading psychiatric hospital in Egypt. Her research contributions have led to publications within the Journal of International Psychiatry and the Surgeon General’s Report.

Message Presenter

Patti Peeples, RPh, PhD, CEO and Founder, HealthEconomics.com, and Principal Researcher, HE Institute

Dr. Patti Peeples is a health economist, pharmacist, and researcher with 30 years of experience in healthcare outcomes improvement. She is Founder and CEO of HealthEconomics.com, the world’s largest resource portal connecting stakeholders in health economics & outcomes research (HEOR), market access and real world evidence. She is Principal Researcher at HE Institute, a strategic consultancy devoted to value demonstration communication. Dr. Peeples has served in senior positions in Medical Affairs, HEOR and Marketing for pharma organizations and is on the Board of Grants for the American Foundation for Pharmaceutical Education. She serves on editorial boards for Journal of Managed Care Pharmacy and Journal of Clinical Pathways. Peeples, a frequent keynote speaker at major medical meetings, has authored 90 peer-reviewed publications on healthcare cost-effectiveness. She holds a PhD in Health Economics from the University of the Sciences in Philadelphia as well as an MS in Pharmaceutical Marketing and a BS with Clinical Residency in Pharmacy.

Message Presenter

Mary Beth Ritchey, PhD, Director, Epidemiology, Medical Devices, RTI Health Solutions

Mary Beth Ritchey, PhD, is the Director, Epidemiology, Medical Devices & Real-World Evidence at RTI-HS. In her role, Dr. Ritchey is responsible for the scientific, technical and logistic aspects of projects including noninterventional safety, effectiveness and utilization studies, regulatory landscape analysis and consultation on timing, design and practical application of methods for real-world studies. Before joining RTI-HS, Dr. Ritchey worked in government and industry. At the FDA, she managed the device Postmarket Surveillance Studies program and was engaged with real-world evidence initiatives (e.g., Sentinel). At Merck, she developed tools, collaborations and a continuous learning organization for Comparative and Outcomes Evidence. At Procter & Gamble, she enhanced the signal and risk management programs, integrating new data sources. She obtained masters and doctorate degrees in Epidemiology from the UNC Gillings School of Global Public Health and holds an adjunct faculty appointment in the Center for Pharmacoepidemiology and Treatment Science at Rutgers University.

Message Presenter